10x Genomics, Inc. TXG
54.99 USD -3.20 (-5.50%)
Regular-session close
55.46 +0.47 +0.85%
Pre-market · Nov 17, 8:34 AM ET
54.46 Day range 56.52
15.18 52-week range 102.81
- YTD
- +237.16%
- 1 year
- +250.25%
News
benzinga.com 10x Genomics Collaborates With Charité And Seoul National University On Identifying Blood-Based Biomarkers Of Disease Activity And Treatment Response For Autoimmune Disease Collaborations with Charité and DRFZ, and with Seoul National University, aim to identify biomarkers of disease activity and treatment response using 10x's Flex Apex platformPLEASANTON, Calif., Nov.…
zacks.com 10x Genomics' Xenium Platform to Support Breast Cancer Biomarker Study TXG's Xenium platform is set to power a 500-patient breast cancer biomarker study, expanding its oncology research footprint and precision diagnostics potential.benzinga.com 10x Genomics' Xenium Platform To Be Deployed By Fudan University Shanghai Cancer Center, Shanghai Precision Diagnostics In 24-Month Trial 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, today announced that Fudan University Shanghai Cancer Center (FUSCC)…
prnewswire.com Shanghai Precision Diagnostics and Fudan University Shanghai Cancer Center Launch Breast Cancer Biomarker Study Using 10x Genomics' Xenium Platform Study aims to identify biomarkers that could predict how patients with breast cancer respond to neoadjuvant therapy PLEASANTON, Calif., Nov. 10, 2026 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG),…benzinga.com JP Morgan Maintains Neutral on 10x Genomics, Lowers Price Target to $65 JP Morgan analyst Casey Woodring maintains 10x Genomics (NASDAQ:TXG) with a Neutral and lowers the price target from $70 to $65.
benzinga.com Barclays Maintains Overweight on 10x Genomics, Lowers Price Target to $70 Barclays analyst Luke Sergott maintains 10x Genomics (NASDAQ:TXG) with a Overweight and lowers the price target from $110 to $70.
benzinga.com UBS Maintains Neutral on 10x Genomics, Lowers Price Target to $61 UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:TXG) with a Neutral and lowers the price target from $90 to $61.
benzinga.com Citigroup Maintains Neutral on 10x Genomics, Raises Price Target to $60 Citigroup analyst Albert Hu maintains 10x Genomics (NASDAQ:TXG) with a Neutral and raises the price target from $50 to $60.
benzinga.com Stifel Maintains Buy on 10x Genomics, Raises Price Target to $68 Stifel analyst Daniel Arias maintains 10x Genomics (NASDAQ:TXG) with a Buy and raises the price target from $50 to $68.
benzinga.com 10x Genomics Raises FY2026 Sales Guidance from $610.000M-$630.000M to $625.000M-$635.000M vs $619.854M Est 10x Genomics (NASDAQ:TXG) raises FY2026 sales outlook from $610.000 million-$630.000 million to $625.000 million-$635.000 million vs $619.854 million estimate.
benzinga.com Vertiv, Evercore, Brinker, GE HealthCare And Other Big Stocks Moving Higher On Wednesday U.S. stocks mixed; Dow gained ~100 points. Vertiv jumped 13.3% on strong results and raised guidance; Ultralife soared 145.8% on buyout news.
